Filtros de búsqueda

Lista de obras de James L. Gulley

(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment

artículo científico publicado en 2014

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer

artículo científico publicado en 2020

A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema

artículo científico publicado en 2019

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

artículo científico publicado en 2019

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

scientific article published on 08 October 2019

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.

artículo científico publicado en 2016

A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

artículo científico publicado en 2018

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

artículo científico publicado en 2018

A case report of multiple primary prostate tumors with differential drug sensitivity

artículo científico publicado en 2020

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.

artículo científico publicado en 2014

A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion

artículo científico publicado en 2018

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

artículo científico publicado en 2004

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

artículo científico publicado en 2014

A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1

artículo científico publicado en 2003

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

artículo científico publicado en 2017

A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer

artículo científico publicado en 2010

A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local defi

artículo científico publicado en 2006

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer

artículo científico publicado en 2014

A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer

artículo científico publicado en 2004

A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver

artículo científico publicado en 2011

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

article

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer

artículo científico publicado en 2011

A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors

scientific article published on 01 May 2006

A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.

artículo científico publicado en 2008

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

artículo científico publicado en 2005

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

artículo científico publicado en 2006

A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229)

artículo científico publicado en 2006

A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases

artículo científico publicado en 2005

A retrospective study of the time to clinical endpoints for advanced prostate cancer

artículo científico publicado en 2005

A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients

artículo científico publicado en 2010

ABO blood type correlates with survival on prostate cancer vaccine therapy

artículo científico publicado en 2015

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody

artículo científico publicado en 2017

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

scholarly article by Fatima Karzai et al published 4 December 2018 in Journal for Immunotherapy of Cancer

Adding fuel to the fire: immunogenic intensification

artículo científico publicado en 2014

An update on androgen deprivation therapy for prostate cancer ⬇️

artículo científico publicado el 29 de octubre de 2010

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.

artículo científico publicado en 2016

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy

artículo científico publicado en 2016

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

artículo científico publicado en 2017

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

artículo científico publicado en 2005

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

artículo científico publicado en 2017

Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination ⬇️

artículo científico publicado el 26 de octubre de 2010

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy

artículo científico publicado en 2008

Androgen deprivation therapy for prostate cancer

artículo científico publicado en 2005

Anti-PD-L1 Treatment Induced Central Diabetes Insipidus

artículo científico publicado en 2017

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

artículo científico publicado en 2005

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

artículo científico publicado en 2015

Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment

scientific article published on 01 April 2020

Augmented Radiologist Workflow Improves Report Value and Saves Time: A Potential Model for Implementation of Artificial Intelligence

artículo científico publicado en 2020

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

artículo científico publicado en 2020

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

artículo científico publicado en 2017

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

scientific article published on 01 July 2020

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

scientific article published on 01 December 2020

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial

scientific article published on 12 March 2020

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

artículo científico publicado en 2020

Cabozantinib plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer

artículo científico publicado en 2020

Cancer vaccines: current directions and perspectives in prostate cancer

artículo científico publicado en 2009

Cancer vaccines: moving beyond current paradigms

artículo científico publicado en 2007

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

artículo científico publicado en 2024

Checkpoint and PARP inhibitors, for whom and when

artículo científico publicado en 2017

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Metastatic Genitourinary Cancer Patients

artículo científico publicado en 2020

Clinical evaluation of TRICOM vector therapeutic cancer vaccines

artículo científico publicado en 2012

Clinical safety of a viral vector based prostate cancer vaccine strategy

artículo científico publicado en 2007

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

artículo científico publicado en 2012

Combining Vaccines with Conventional Therapies for Cancer

artículo científico publicado en 2007

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

artículo científico publicado en 2005

Combining immunotherapies for the treatment of prostate cancer

artículo científico publicado en 2017

Combining radiation and immunotherapy for synergistic antitumor therapy.

artículo científico publicado en 2009

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

artículo científico publicado en 2018

Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors.

artículo científico publicado en 2016

Costimulatory molecules as adjuvants for immunotherapy

artículo científico publicado en 2006

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

artículo científico publicado en 2020

Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.

artículo científico publicado en 2013

Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells.

artículo científico publicado en 2015

Developing immunotherapy strategies in the treatment of prostate cancer

artículo científico publicado en 2016

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.

artículo científico publicado en 2019

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine

artículo científico publicado en 2013

Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis

artículo científico publicado en 2006

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

artículo científico

Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer

scientific article published on 01 January 2003

Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer

artículo científico publicado en 2005

Dramatic and prolonged PSA response after retreatment with a PSA vaccine.

artículo científico publicado en 2013

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

artículo científico publicado en 2020

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management

scientific article published on 01 November 2020

Early treatment gets the benefit

scientific article published on 01 November 2006

Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot"

artículo científico publicado en 2017

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression.

artículo científico publicado en 2015

Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer

artículo científico publicado en 2013

Effects of conventional therapeutic interventions on the number and function of regulatory T cells.

scientific article published on October 2013

Efficacy and immune-related adverse event associations in avelumab-treated patients

scientific article published on 01 November 2020

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

scientific article published on 01 September 2020

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

artículo científico publicado en 2019

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role

artículo científico publicado en 2012

Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

artículo científico publicado en 2019

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

artículo científico publicado en 2012

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer

artículo científico publicado en 2008

Enhancing efficacy of therapeutic vaccinations by combination with other modalities

artículo científico publicado en 2007

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells.

artículo científico publicado en 2015

Even More Cost Savings? ⬇️

artículo científico publicado el 1 de julio de 2006

Exploiting synergy: immune-based combinations in the treatment of prostate cancer

artículo científico publicado en 2014

Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report

artículo científico publicado en 2020

Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study

artículo científico publicado en 2019

Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment

article

First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors

scientific article published on 21 August 2018

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival

artículo científico publicado en 2013

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer

artículo científico publicado en 2011

Future directions in tumor immunotherapy: CTLA4 blockade

artículo científico publicado en 2007

Hepcidin, anaemia, and prostate cancer ⬇️

artículo científico publicado el 1 de febrero de 2011

Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer

artículo científico publicado en 2011

Humoral response to a viral glycan correlates with survival on PROSTVAC-VF

artículo científico publicado en 2014

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

artículo científico publicado en 2002

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein

artículo científico publicado en 2013

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.

artículo científico publicado en 2013

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.

artículo científico publicado en 2014

Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).

artículo científico publicado en 2007

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301).

artículo científico publicado en 2014

IgG Responses to Tissue‐Associated Antigens as Biomarkers of Immunological Treatment Efficacy ⬇️

artículo científico publicado el 19 de diciembre de 2010

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa

artículo científico publicado en 2022

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer

artículo científico publicado en 2013

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab

artículo científico publicado en 2019

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

artículo científico publicado en 2009

Immunologic monitoring of cellular immune responses in cancer vaccine therapy

artículo científico publicado en 2011

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications

artículo científico publicado en 2014

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

artículo científico publicado en 2011

Immunotherapy for prostate cancer: what's the future?

artículo científico publicado en 2006

Immunotherapy in genitourinary malignancies

artículo científico publicado en 2016

Immunotherapy of Prostate Cancer: Facts and Hopes.

artículo científico publicado en 2017

Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer

artículo científico publicado en 2012

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM

article published in 2014

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells

artículo científico publicado en 2013

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

artículo científico publicado en 2007

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer

artículo científico publicado en 2003

Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine

artículo científico publicado en 2011

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

artículo científico publicado en 2020

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody

artículo científico publicado en 2014

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

scientific article published on 10 February 2012

Ipilimumab in prostate cancer

artículo científico

Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells

artículo científico publicado en 2011

Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial)

artículo científico publicado en 2018

Moving the goal posts in prostate cancer trials

scientific article published on 18 February 2015

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report

scientific article published on 18 December 2018

National Cancer Institute intramural approach to advanced prostate cancer

artículo científico publicado en 2002

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

scientific article published on 01 March 2020

New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy

artículo científico publicado en 2009

Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers

scientific article published on 02 May 2016

Nivolumab: promising survival signal coupled with limited toxicity raises expectations

artículo científico publicado en 2014

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

artículo científico publicado en 2010

PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma

artículo científico publicado en 2007

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients

PSA-based vaccines for the treatment of prostate cancer

artículo científico publicado en 2006

Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy

artículo científico publicado en 2014

Paradigm shifts in cancer vaccine therapy.

scientific article published on 28 March 2008

Pembrolizumab: patient selection or immune intensification?

scientific article published on 01 October 2018

Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases

artículo científico publicado en 2007

Perspectives on the clinical development of immunotherapy in prostate cancer.

artículo científico publicado en 2018

Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors

artículo científico publicado en 2018

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

scientific article published on 29 March 2020

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

scientific article published on 11 September 2020

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury

artículo científico publicado en 2017

Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors

artículo científico publicado en 2019

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

artículo científico publicado en 2015

Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma

scientific article published on 20 June 2019

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

artículo científico publicado en 2002

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

artículo científico publicado en 2013

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

artículo científico publicado en 2004

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

scientific article published on 05 September 2019

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

artículo científico publicado en 2013

Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer

article

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses

artículo científico publicado en 2015

Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer

artículo científico publicado en 2013

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity

artículo científico publicado en 2013

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

artículo científico publicado en 2010

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.

artículo científico publicado en 2016

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2019

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

artículo científico publicado en 2008

Poxviral vectors for cancer immunotherapy

artículo científico publicado en 2012

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients

artículo científico publicado en 2014

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer

scientific article published on 01 May 2007

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

artículo científico publicado en 2018

Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy

artículo científico publicado en 2007

Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST

artículo científico publicado en 2016

Product review: avelumab, an anti-PD-L1 antibody

scientific article published on 20 December 2018

Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy

artículo científico publicado en 2005

Promising novel immunotherapies and combinations for prostate cancer

artículo científico publicado en 2009

Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.

artículo científico publicado en 2016

Prospects for the future of prostate cancer vaccines.

artículo científico publicado en 2015

Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time

artículo científico publicado en 2008

Prostate cancer immunotherapy

artículo científico publicado en 2011

Prostate cancer immunotherapy: the path forward

artículo científico publicado en 2017

Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy

artículo científico publicado en 2017

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

artículo científico publicado en 2009

Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide

artículo científico publicado en 2003

Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T

scientific article published on 07 March 2020

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

scholarly article by Jason M Redman et al published 18 September 2018 in Journal for Immunotherapy of Cancer

Radium-223 in prostate cancer: emitting the right signals

artículo científico publicado en 2016

Radium-223 mechanism of action: implications for use in treatment combinations

scientific article published on 11 November 2019

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

artículo científico publicado en 2004

Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).

artículo científico publicado en 2015

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

artículo científico publicado en 2012

Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies

artículo científico publicado en 2014

Reply to L. León et al

Resources Required for Semi-Automatic Volumetric Measurements in Metastatic Chordoma: Is Potentially Improved Tumor Burden Assessment Worth the Time Burden?

artículo científico publicado en 2015

Response to: Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors; more common than we thought

artículo científico publicado en 2020

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

artículo científico publicado en 2016

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

artículo científico publicado en 2017

Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone

artículo científico publicado en 2006

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

scholarly article by Clint T Allen et al published 3 May 2019 in Journal for Immunotherapy of Cancer

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

artículo científico publicado en 2008

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

artículo científico publicado en 2016

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response

scientific article published on 06 October 2020

Serum antibodies to blood group A predict survival on PROSTVAC-VF.

artículo científico publicado en 2013

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy

scientific article published on 17 April 2019

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

artículo científico publicado en 2018

Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature

artículo científico publicado en 2007

Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer ⬇️

artículo científico publicado el 1 de febrero de 2011

Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity

artículo científico publicado en 2013

Strategies for improving the management of immune-related adverse events

scientific article published on 01 December 2020

Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.

artículo científico publicado en 2012

Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer

artículo científico publicado en 2003

Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion

scientific article published on 01 October 2019

Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges

artículo científico publicado en 2008

TRICOM vector based cancer vaccines.

artículo científico publicado en 2006

The Current and Emerging Role of Immunotherapy in Prostate Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2010

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

artículo científico publicado en 2016

The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer

scientific article published on 01 November 2020

The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance

artículo científico publicado en 2019

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

scientific article published on 20 December 2016

The evolving role of immunotherapy in prostate cancer

artículo científico publicado en 2016

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.

artículo científico publicado en 2015

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.

artículo científico publicado en 2015

The impact of leukapheresis on immune-cell number and function in patients with advanced cancer

artículo científico publicado en 2015

The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology

artículo científico publicado en 2012

The role of soluble CD40L in immunosuppression

artículo científico publicado en 2013

Therapeutic Cancer Vaccine Fulfills the Promise of Immunotherapy in Prostate Cancer ⬇️

artículo científico publicado el 1 de enero de 2011

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression ⬇️

artículo científico publicado el 26 de agosto de 2010

Therapeutic cancer vaccines.

artículo científico publicado en 2014

Therapeutic prostate cancer vaccines: a review of the latest developments

artículo científico publicado en 2008

Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications

artículo científico publicado en 2013

Therapeutic vaccines for prostate cancer

artículo científico publicado en 2006

Therapeutic vaccines for prostate cancer: a review of clinical data

artículo científico publicado en 2005

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.

artículo científico publicado en 2010

Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.

artículo científico publicado en 2010

Treatment options for androgen-independent prostate cancer.

artículo científico publicado en 2003

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy ⬇️

artículo científico publicado el 24 de noviembre de 2010

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

scientific article published on 07 July 2020

Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.

artículo científico publicado en 2013

Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

artículo científico publicado en 2020

Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans

artículo científico publicado en 2004

Vaccines as an Integral Component of Cancer Immunotherapy.

artículo científico publicado en 2018

Vaccines as monotherapy and in combination therapy for prostate cancer

artículo científico publicado en 2010

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy

artículo científico publicado en 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda